Table 2 Grade 3/4/5 adverse events in overall population and according to the treatment modality.

From: Intra-arterial hepatic beads loaded with irinotecan (DEBIRI) with mFOLFOX6 in unresectable liver metastases from colorectal cancer: a Phase 2 study

Toxicity

 

Grade 3/4/5 toxicity

 

All, N = 57

Unilobar, N = 36

Bilobar, N = 21

All

38 (66.7)

19 (52.8)

19 (90.5)

Non-hematologic

  Any non-hematologic

27 (47.4)

12 (33.3)

15 (71.4)

   Asthenia

3 (5.3)

0

3 (14.3)

   Hypertension

1 (1.8)

0

1 (4.8)

 Any gastrointestinal

20 (35.1)

9 (25.0)

11 (52.4)

   Nausea

3 (5.3)

1 (2.8)

2 (9.5)

   Vomiting

3 (5.3)

3 (8.3)

0

   Diarrhoea

7 (12.3)

3 (8.3)

4 (19.0)

   Abdominal pain

8 (14.0)

2 (5.6)

6 (28.6)

   Small bowel obstruction

2 (3.5)

1 (2.8)

1 (4.8)

 Any extrahepatic perfusion

7

2 (5.6)

5 (23.8)

   Peritonitis

1 (1.8)

0

1 (4.8)

   Pancreatitis

5 (8.8)

1 (2.8)

4 (19)

   Cholecystitis

3 (5.3)

2 (5.6)

1 (4.8)

Hematologic

20 (35.1)

11 (30.6)

9 (42.9)

  Anemia

3 (5.3)

2 (5.6)

1 (4.8)

  Thrombocytopenia

3 (5.3)

0

3 (14.3)

  Lymphopenia

2 (3.5)

2 (5.6)

0

  Leucopenia

1 (1.8)

1 (2.8)

0

  Neutropenia

14 (24.6)

6 (16.7)

8 (38.1)

  Febrile neutropenia

3 (5.3)

2 (5.6)

1 (4.8)

Back to article page